Title: Epitope mapping of BP230 leading to a novel enzyme‐linked immunosorbent assay for autoantibodies in bullous pemphigoid
Abstract: British Journal of DermatologyVolume 166, Issue 5 p. 964-970 CLINICAL AND LABORATORY INVESTIGATIONS Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid I.M. Blöcker, I.M. Blöcker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorC. Dähnrich, C. Dähnrich Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorC. Probst, C. Probst Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorL. Komorowski, L. Komorowski Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorS. Saschenbrecker, S. Saschenbrecker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorW. Schlumberger, W. Schlumberger Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorW. Stöcker, W. Stöcker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorD. Zillikens, D. Zillikens Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanySearch for more papers by this authorE. Schmidt, E. Schmidt Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany Comprehensive Centre for Inflammation Medicine, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanySearch for more papers by this author I.M. Blöcker, I.M. Blöcker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorC. Dähnrich, C. Dähnrich Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorC. Probst, C. Probst Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorL. Komorowski, L. Komorowski Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorS. Saschenbrecker, S. Saschenbrecker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorW. Schlumberger, W. Schlumberger Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorW. Stöcker, W. Stöcker Institute of Experimental Immunology, EUROIMMUN AG, Seekamp 31, 23560 Lübeck, GermanySearch for more papers by this authorD. Zillikens, D. Zillikens Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanySearch for more papers by this authorE. Schmidt, E. Schmidt Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany Comprehensive Centre for Inflammation Medicine, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanySearch for more papers by this author First published: 13 January 2012 https://doi.org/10.1111/j.1365-2133.2012.10820.xCitations: 62 Enno Schmidt. E-mail: [email protected] Funding sources: This work was supported by the Deutsche Forschungsgemeinschaft through the Schleswig-Holstein Cluster of Excellence (EXC 306/1) to E.S. and D.Z. Conflicts of interest: I.M.B., C.D., C.P., L.K. and S.S. are employees of EUROIMMUN AG, Lübeck, Germany. W.Sc. and W.St. are board members of EUROIMMUN AG. D.Z. has received funding for scientific cooperation from EUROIMMUN AG. E.S. declares no conflict of interest. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Background Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by circulating autoantibodies against BP180 and BP230. For BP180, the NC16A domain has previously been identified as the main antigenic target in BP, while data about the diagnostic value of epitopes on BP230 were inconclusive. Objectives To identify the most appropriate epitopes on BP230 to be applied in a simple, sensitive, and highly specific enzyme-linked immunosorbent assay (ELISA) for routine detection of serum autoantibodies. Methods Ten overlapping linear fragments covering the whole length of BP230 were expressed in Escherichia coli. Based on Western blot analysis with sera from patients with BP (n = 49) and healthy controls (n = 94), the diagnostic performance of the fragments was compared by receiver operating characteristics curve analysis. The BP230-C3 fragment comprising the C-terminal portion (amino acids 2326–2649) was subsequently applied in a novel ELISA. The operating characteristics of this ELISA were analysed by probing sera from patients with BP (n = 118), pemphigus vulgaris (n = 50), rheumatoid arthritis and other inflammatory arthritides (n = 170), and systemic lupus erythematosus (n = 56), and from healthy blood donors (n = 483). Results Among all the fragments, BP230-C3 provided the best efficiency in serologically diagnosing BP by Western blot. An ELISA employing BP230-C3 revealed a diagnostic sensitivity of 56·8% and specificity of 97·6%. Its diagnostic added value amounted to 4·2% compared with the anti-BP180-NC16A-4X ELISA alone. Conclusions Recombinant BP230-C3 is a suitable target antigen for the detection of serum autoantibodies against BP230. Citing Literature Supporting Information Table S1. PCR amplification of BP230 fragments. Filename Description BJD_10820_sm_TableS1.doc45.5 KB Supporting info item Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume166, Issue5May 2012Pages 964-970 RelatedInformation
Publication Year: 2012
Publication Date: 2012-04-04
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 80
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot